HIV Prevention Trials Network Announce Findings from HPTN 052

The HIV Prevention Trials Network (HPTN) announced findings from HPTN 052, a study to evaluate the immediate versus delayed use of antiretroviral therapy by HIV-infected individuals on transmission to uninfected partners and health of the infected individual. The study showed that initiation of ART by HIV-­‐infected individuals substantially protected their HIV-­uninfected sexual partners from acquiring HIV infection, with a 96 percent reduction in risk of HIV transmission. HPTN 052 is the first randomized clinical trial to show that treating an HIV­‐infected individual with ART can reduce the risk of sexual transmission of HIV to an uninfected partner. The full announcement is below.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account